Global HTA Divergence

MarcusWelcome to Access Brief, the daily AI podcast on HEOR, HTA, and market access. I'm Marcus, with Sara. Today: HTA in the Gulf, Brazilian pricing, African RWE, Japanese gene therapy, and Australian digital health. Let's get into it.

MarcusFirst, HTA methodologies in the Gulf Cooperation Council. Saudi Arabia and UAE are developing centralized frameworks, but fragmentation persists. Each country prioritizes different evidence requirements—Saudi emphasizes cost-effectiveness, UAE focuses on budget impact. This creates compliance challenges for manufacturers. The push for harmonization is slow, with no unified submission platform yet. Companies must tailor dossiers per country, increasing resource demands. The region's economic diversification is driving HTA adoption, but capacity gaps remain. Sara, what's your take on commercial implications?

SaraCommercially, it's a strategic minefield. Gulf countries' sovereign wealth funds can bypass traditional HTA for high-value assets, but smaller markets still rely on cost-effectiveness thresholds. The real issue is inconsistency in how they apply value frameworks. Saudi's inclusion criteria are narrower than UAE's, creating access delays. Manufacturers need country-specific evidence strategies, not one-size-fits-all approaches. The economic argument for harmonization is clear, but political barriers are significant. Marcus, do you see HTA bodies in these regions ever aligning on core methodologies?

MarcusUnlikely in the near term. Their healthcare systems operate on different funding models and have distinct public health priorities. UAE's focus on innovation contrasts with Saudi's emphasis on cost containment. This divergence isn't just bureaucratic—it reflects underlying policy goals. Until there's regional economic integration, HTA harmonization remains aspirational. The fragmentation forces companies to invest in local partnerships, which can be advantageous for long-term market positioning but adds upfront complexity.

SaraShifting to Brazil's pricing policy reforms. The government is expanding mandatory price controls beyond generics to include patented biologics. The new framework requires real-world evidence for price adjustments, creating uncertainty for manufacturers. Brazil's reference pricing system now includes more Latin American countries, increasing pressure on global pricing strategies. The market's size justifies the complexity, but compliance risks are rising. Marcus, how does this intersect with global value demonstration?

MarcusBrazil's approach undermines international value frameworks by prioritizing affordability over clinical benefits. Their RWE requirements for pricing adjustments lack standardized methodology, leading to arbitrary decisions. Manufacturers must generate Brazil-specific evidence that doesn't align with HTA standards globally. This creates a parallel evidence generation system, increasing costs. The reference pricing expansion amplifies cross-border spillover effects, making Brazil a pricing anchor for the region. Sara, isn't this justifiable for a market with limited healthcare budgets?

SaraJustifiable? Perhaps. But it's a dangerous precedent. Brazil's model encourages other emerging markets to adopt similar approaches, fragmenting global value narratives. The focus on affordability ignores innovation value, potentially stifling R&D investment. Companies need to reframe evidence strategies to address local cost realities without compromising global value claims. The challenge is balancing country-specific requirements with consistent value messaging. Marcus, do you see Brazil's RWE requirements becoming a template elsewhere?

MarcusAbsolutely. Similar patterns are emerging in Southeast Asia. Vietnam and Thailand are watching Brazil's model closely. The RWE demand will likely expand, but with even less methodological rigor. Brazil's approach signals a shift toward politically driven pricing, where evidence is secondary to budgetary constraints. This forces manufacturers to develop dual-track evidence strategies—robust HTA submissions for developed markets and simplified economic models for price-controlled economies. The resource allocation is unsustainable long-term.

SaraMoving to RWE integration in African healthcare systems. Kenya and Nigeria are piloting RWE frameworks for neglected diseases, but data infrastructure is inadequate. Mobile health platforms offer opportunities, yet interoperability remains a barrier. The African Medicines Agency is developing guidelines, but implementation lags. Manufacturers see potential for African RWE to support global submissions, but quality concerns persist. Marcus, is RWE viable in these contexts?

MarcusViable? Only if we lower expectations. African RWE lacks longitudinal data and standardized endpoints. The mobile health initiatives are promising but limited to specific populations. Using such data for global HTA submissions would undermine scientific credibility. The real opportunity is in local market access, not international evidence generation. Africa's value lies in patient diversity for rare disease studies, not as a standalone RWE source. Sara, aren't you underestimating the potential for African data to fill global evidence gaps?

SaraNot at all. The methodological risks are too high. African healthcare systems face unique challenges—variable diagnostic capabilities, comorbidities, and environmental factors—that confound data interpretation. Manufacturers should focus on building local partnerships for targeted studies, not repurposing fragmented data for global submissions. The African Medicines Agency's guidelines are a step forward, but capacity building takes time. Until then, RWE in Africa should remain context-specific. Marcus, how do you see this evolving?

MarcusEvolution requires investment in digital infrastructure. Public-private partnerships could establish standardized data repositories, but funding is scarce. The pandemic demonstrated Africa's potential for rapid data collection, yet sustainability remains an issue. The focus should be on pragmatic RWE for local HTA decisions, not global evidence synthesis. Africa's contribution to HEOR will be in demonstrating real-world effectiveness in diverse populations, not as a replacement for randomized trials.

SaraFinally, Japan's gene therapy HEOR landscape. The government is revising cost-effectiveness thresholds for innovative therapies, but orphan drug policies create inconsistencies. Japan's emphasis on long-term outcomes clashes with global preference for surrogate endpoints. The system rewards incremental innovation over breakthroughs, creating access barriers for novel modalities. Marcus, how does Japan's approach impact global evidence strategies?

MarcusJapan forces manufacturers to develop Japan-specific endpoints, increasing trial complexity. Their focus on real-world evidence post-approval creates uncertainty for market entry. The orphan drug designation system prioritizes rarity over clinical need, misallocating resources. Companies must adapt HEOR strategies to address Japan's unique value framework, which doesn't align with international standards. This fragmentation complicates global value demonstration. Sara, isn't Japan's focus on long-term outcomes a strength?

SaraA strength in theory, but a barrier in practice. Japan's demand for 10-year data for gene therapies delays market access without added value. Their HTA system lacks flexibility for rapidly evolving science. The orphan drug policy prioritizes rare diseases over high-impact conditions, limiting patient access. Manufacturers need Japan to harmonize with global endpoints while accommodating local evidence requirements. The current system stifles innovation for both local and global markets.

MarcusContrary views aside, the global HTA divergence is accelerating. Companies must navigate fragmented systems while maintaining consistent value narratives. The strain on evidence generation resources is unsustainable. Sara, your final thought?

SaraMarket access teams need agile evidence strategies that balance global standards with local realities. The future belongs to those who can adapt without compromising scientific rigor. Marcus?

MarcusDivergence demands investment in modular evidence frameworks. Standardization remains aspirational; adaptability is essential. Back tomorrow on Access Brief. Show notes at outcomes-analytica.no.